Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

Abstract Background Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovas...

Full description

Saved in:
Bibliographic Details
Main Authors: Lynne Chepulis, Mark Rodrigues, Han Gan, Rawiri Keenan, Tim Kenealy, Rinki Murphy, Leanne Te Karu, Jo Scott-Jones, Penny Clark, Allan Moffitt, Sara Mustafa, Ross Lawrenson, Ryan Paul
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Health Services Research
Subjects:
SGLT2i
GLP1RA
Type 2 diabetes
Health system access
Online Access:https://doi.org/10.1186/s12913-025-12601-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12913-025-12601-3

Similar Items